Causal Inference and Estimands in Clinical Trials
暂无分享,去创建一个
Bohdana Ratitch | Ilya Lipkovich | Craig H. Mallinckrodt | B. Ratitch | I. Lipkovich | C. Mallinckrodt
[1] J M Robins,et al. Correction for non-compliance in equivalence trials. , 1998, Statistics in medicine.
[2] Jiannan Lu,et al. Principal stratification analysis using principal scores , 2016, 1602.01196.
[3] G. Molenberghs,et al. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice. , 2019, Therapeutic innovation & regulatory science.
[4] Elizabeth A Stuart,et al. Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.
[5] Thomas Permutt,et al. A taxonomy of estimands for regulatory clinical trials with discontinuations , 2016, Statistics in medicine.
[6] B L De Stavola,et al. Methods for dealing with time‐dependent confounding , 2013, Statistics in medicine.
[7] Roderick Little,et al. Intention‐to‐treat analysis with treatment discontinuation and missing data in clinical trials , 2015, Statistics in medicine.
[8] Kosuke Imai,et al. Sharp bounds on the causal effects in randomized experiments with "truncation-by-death" , 2008 .
[9] D. Mehrotra,et al. Rank‐based principal stratum sensitivity analyses , 2013, Statistics in medicine.
[10] Kaspar Rufibach,et al. Treatment effect quantification for time‐to‐event endpoints–Estimands, analysis strategies, and beyond , 2017, Pharmaceutical statistics.
[11] R J Little,et al. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. , 2000, Annual review of public health.
[12] Tyler J VanderWeele,et al. Causal inference under multiple versions of treatment , 2013, Journal of causal inference.
[13] P. Gilbert,et al. Sensitivity Analyses Comparing Time‐to‐Event Outcomes Only Existing in a Subset Selected Postrandomization and Relaxing Monotonicity , 2011, Biometrics.
[14] Tyler J. VanderWeele,et al. Conceptual issues concerning mediation, interventions and composition , 2009 .
[15] Thomas Permutt,et al. Sensitivity analysis for missing data in regulatory submissions , 2016, Statistics in medicine.
[16] T. Speed,et al. On the Application of Probability Theory to Agricultural Experiments. Essay on Principles. Section 9 , 1990 .
[17] Susan M Shortreed,et al. Estimating the optimal dynamic antipsychotic treatment regime: evidence from the sequential multiple‐assignment randomized Clinical Antipsychotic Trials of Intervention and Effectiveness schizophrenia study , 2012, Journal of the Royal Statistical Society. Series C, Applied statistics.
[18] Avi Feller,et al. Bounding, An Accessible Method for Estimating Principal Causal Effects, Examined and Explained , 2017, 1701.03139.
[19] Haoda Fu,et al. A General Framework for Treatment Effect Estimators Considering Patient Adherence , 2020 .
[20] A. Dawid,et al. Causal Inference without Counterfactuals , 2000 .
[21] Deepak L. Bhatt,et al. On the use of propensity scores in case of rare exposure , 2016, BMC Medical Research Methodology.
[22] Y. Lou,et al. Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data , 2018, Journal of biopharmaceutical statistics.
[23] D. Pauler,et al. An Estimator for Treatment Comparisons among Survivors in Randomized Trials , 2005, Biometrics.
[25] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[26] D. Rubin,et al. Principal Stratification in Causal Inference , 2002, Biometrics.
[27] J. Pearl. Causal inference in statistics: An overview , 2009 .
[28] K. Abrams,et al. Simultaneous analysis of quality of life and survival data , 2002, Statistical methods in medical research.
[29] Donald B. Rubin,et al. Estimation of Causal Effects via Principal Stratification When Some Outcomes are Truncated by “Death” , 2003 .
[30] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[31] Baldur P Magnusson,et al. Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by post-randomization events , 2018, 1809.03741.
[32] Joshua D. Angrist,et al. Identification of Causal Effects Using Instrumental Variables , 1993 .
[33] S. Murphy,et al. Optimal dynamic treatment regimes , 2003 .
[34] J. Robins,et al. Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.
[35] T. Richardson. Single World Intervention Graphs ( SWIGs ) : A Unification of the Counterfactual and Graphical Approaches to Causality , 2013 .
[36] M. Gail,et al. Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates , 1984 .
[37] Feng Li,et al. Trimmed means for symptom trials with dropouts. , 2017, Pharmaceutical statistics.
[38] T. Permutt. Effects in Adherent Subjects , 2018, Statistics in Biopharmaceutical Research.
[39] James R Carpenter,et al. Analysis of Longitudinal Trials with Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and Inference via Multiple Imputation , 2013, Journal of biopharmaceutical statistics.
[40] D. Rubin,et al. MULTIPLE IMPUTATIONS IN SAMPLE SURVEYS-A PHENOMENOLOGICAL BAYESIAN APPROACH TO NONRESPONSE , 2002 .
[41] Donald B. Rubin,et al. Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .
[42] S. Pocock,et al. A win ratio approach to comparing continuous non‐normal outcomes in clinical trials , 2016, Pharmaceutical statistics.
[43] T. Permutt. Treatment Effects, Comparisons, and Randomization , 2020, Statistics in Biopharmaceutical Research.
[44] G. Shaw,et al. Maternal pesticide exposure from multiple sources and selected congenital anomalies. , 1999 .
[45] J. Robins. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .
[46] R. D'Agostino. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.
[47] D. Rubin,et al. Bayesian inference for causal effects in randomized experiments with noncompliance , 1997 .
[48] A. P. Dawid,et al. Causal inference without counterfactuals (with Discussion) , 2000 .
[49] D. Rubin. [On the Application of Probability Theory to Agricultural Experiments. Essay on Principles. Section 9.] Comment: Neyman (1923) and Causal Inference in Experiments and Observational Studies , 1990 .
[50] Judea Pearl,et al. Causal Inference in the Health Sciences: A Conceptual Introduction , 2001, Health Services and Outcomes Research Methodology.
[51] Peter C. Austin,et al. A critical appraisal of propensity score matching in the medical literature from 1996 to 2003 , 2008 .
[52] M. Robins James,et al. Estimation of the causal effects of time-varying exposures , 2008 .
[53] Peter C Austin,et al. A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003 , 2008, Statistics in medicine.
[54] Brent A. Johnson,et al. Estimating Mean Response as a Function of Treatment Duration in an Observational Study, Where Duration May Be Informatively Censored , 2004, Biometrics.
[55] D B Rubin,et al. More powerful randomization-based p-values in double-blind trials with non-compliance. , 1998, Statistics in medicine.
[56] G. Molenberghs,et al. Choosing estimands in clinical trials with missing data , 2017, Pharmaceutical statistics.
[57] Michael Rosenblum,et al. Marginal Structural Models , 2011 .
[58] D. Scharfstein,et al. Cautions as Regulators Move to End Exclusive Reliance on Intention to Treat , 2018, Annals of Internal Medicine.
[59] Nicky Best,et al. A causal modelling framework for reference-based imputation and tipping point analysis , 2017, 1705.04506.
[60] Sander Greenland,et al. Causal Diagrams , 2011, International Encyclopedia of Statistical Science.
[61] S. Murphy,et al. An experimental design for the development of adaptive treatment strategies , 2005, Statistics in medicine.
[62] J. Lunceford,et al. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study , 2004, Statistics in medicine.
[63] Fang Liu,et al. Missing data in clinical trials: control‐based mean imputation and sensitivity analysis , 2017, Pharmaceutical statistics.
[64] J. Lachin. Worst-rank score analysis with informatively missing observations in clinical trials. , 1999, Controlled clinical trials.
[65] Erica E M Moodie,et al. Demystifying Optimal Dynamic Treatment Regimes , 2007, Biometrics.
[66] Erik T Parner,et al. Causal inference in survival analysis using pseudo‐observations , 2017, Statistics in medicine.
[67] Björn Bornkamp,et al. Estimating the Treatment Effect in a Subgroup Defined by an Early Post-Baseline Biomarker Measurement in Randomized Clinical Trials With Time-To-Event Endpoint , 2018, Statistics in Biopharmaceutical Research.
[68] Richard J. Cook,et al. Does Cox analysis of a randomized survival study yield a causal treatment effect? , 2015, Lifetime data analysis.
[69] D. Mehrotra,et al. A Comparison of Eight Methods for the Dual‐Endpoint Evaluation of Efficacy in a Proof‐of‐Concept HIV Vaccine Trial , 2006, Biometrics.
[70] Brent A. Johnson,et al. Semiparametric inference in observational duration-response studies, with duration possibly right-censored , 2005 .
[71] Elizabeth A Stuart,et al. On the use of propensity scores in principal causal effect estimation , 2009, Statistics in medicine.
[72] D. Rubin. Multiple imputation for nonresponse in surveys , 1989 .
[73] Lena Osterhagen,et al. Multiple Imputation For Nonresponse In Surveys , 2016 .
[74] A. Cipriani,et al. What is an intention to treat analysis? , 2008, Epidemiologia e Psichiatria Sociale.
[75] Tyler J VanderWeele,et al. Principal Stratification -- Uses and Limitations , 2011, The international journal of biostatistics.
[76] Heinz Schmidli,et al. Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence , 2019, Statistics in medicine.
[77] Joseph G Ibrahim,et al. Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study. , 2012, Biometrika.